Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUPER study
2024-514206-31-00Phase 2Completed
- Sponsor
- Dr.Antonio Calles Blanco
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lurbinectedin in small cell lung cancer (SCLC), sponsored by Dr.Antonio Calles Blanco. Started Jul 2024; status: completed.
02
Drugs
pembrolizumablurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-514206-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514206-31-00.